Navigation Links
UPDATE: Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
Date:7/22/2009

Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference

Access to Provide Details on MuGard Launch in Europe

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that Jeffrey B. Davis, President & CEO, will present at the Jesup & Lamont 2009 Growth Stock Conference organized by the LifeTech Capital Group on Thursday, July 30, 2009 at 10:45 am EDT. The presentation will occur live and will be held at the Waldorf Astoria Boca Beach Club in Boca Raton, Florida.

"We are pleased to have the opportunity to present Access Pharmaceuticals to the large group of institutional and retail investors that attend Jesup's annual growth stock conference," stated Jeffrey B. Davis, Access' President & CEO. "The conference provides a forum for Access to highlight in many product programs, and specifically the very significant and positive initial results and feedback from the commercial launch of MuGard, our FDA approved treatment for oral mucositis. Initial clinical feedback and experience exceeds our expectations."

About Access: Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PA Game Commission: EHD Outbreak Update: Test Results Confirm EHD In Beaver County
2. UPDATE: Governor Rendell to Fight to Cover All Pennsylvanians During Statewide Bus Tour
3. Update: SpineMark Expands Management Team to Build Spine Care Network
4. Skin Cancer Prevention Update:
5. Update: Oscar-Nominated Actress Signs on as Neutrogena(R) Brand Ambassador
6. VoIP-PAL.com, Inc. (Pink Sheets: VPLM.PK - News) UPDATE: Announces First Award Recipient of TalkfortheCure(TM) Dollars
7. UPDATE: Retirement Living TV Partners With Maryland Public Television to Address the Issue of Healthcare in America Through Its Series Healthcare 08: Search for Solutions
8. UPDATE: Celebrating UC Success Announces Essay Contest Winners
9. UPDATE: Defense Health Board Traumatic Brain Injury Family Caregivers Panel
10. TCT update: press conference schedule announced for TCT
11. Economic Update: You Should Invest (in Your Appearance)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... This month, the CEO and Clinical Director ... their drug rehab center in Delray Beach, Florida has been changed from Sober Living ... such as Philip Seymour Hoffman and Chris Farley are dying from heroin overdoses, but ...
(Date:1/19/2017)... ... 2017 , ... WhoHaha , a digital media company dedicated to creating ... to produce a three-part video series that uses humor to highlight ways to improve ... of AHA’s Healthy For Good™ movement, which is designed to inspire all Americans to ...
(Date:1/19/2017)... ... 2017 , ... Cosmetic Town, an online plastic surgery community, begins 2017 with ... easier for their readers to get the information they desire. The procedures are now ... techniques used on those particular areas. , “We are excited to streamline our listings ...
(Date:1/19/2017)... ... January 19, 2017 , ... Catalent Pharma Solutions, the ... and consumer health products, today announced that it will be co-hosting a workshop ... excipients and drug delivery solutions to health industries worldwide. The one day event ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... recently provided a new $11,250,000 senior credit facility to Sunrise, Florida-based Management Health ... facility were used to facilitate a recapitalization of MedPro led by Harren Equity ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Jan. 19, 2017  Sensus Healthcare, Inc. (NASDAQ: ... specializing in the treatment of non-melanoma skin cancers ... superficial radiation therapy, today announced that it will ... financial results on Thursday, February 2, 2017 after the ... a conference call with the investment community on Thursday, ...
(Date:1/19/2017)... -- New Review of Safinamide - ... and Motor Complications in Mid- to Late-stage Parkinson,s ... ... C Warren Olanow , ... 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late Published recently ...
(Date:1/19/2017)... 2017 The Global Therapy Partnering Terms and ... partnering deals and agreements entered into by the world,s ... - Top deals by value - Deals listed by ... The report provides understanding and access to the ... leading healthcare companies. The report provides an analysis ...
Breaking Medicine Technology: